The introduction of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable excitement within the healthcare community. This groundbreaking dual GIP and GLP-1 target medication suggests to provide significant improvements in body shedding compared to previous therapies. Preliminary patient studies have indicated marked decreases in weight